Cbl-b-IN-2 (Example 8) 是一种口服有效的生物化合物，可抑制泛素蛋白酶体通路中的 E3 酶Casitas b系淋巴瘤原癌基因-b (Cbl-b)。Cbl-b-IN-2 可用于调节免疫系统和易受免疫系统调节的疾病。Cbl-b-IN-2 (Example 8) 还可单独或与一种或多种免疫检查点抑制剂，抗肿瘤剂和放射剂联合应用于癌症。

Cbl-b-IN-2 (Example 8) is an orally bioavailable compound, can inhibit the E3 enzyme Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) in the ubiquitin proteasome pathway. Cbl-b-IN-2 can be used to modulate the immune system and diseases amenable to immune system modulation. Cbl-b-IN-2 (Example 8) also may be administered to an individual with cancer, either alone or as part of a combination, with one or more of an immune checkpoint inhibitor, an anti-neoplastic agent, and radiation agent [1].

Cbl-b-IN-2 (Example 8) is a Cbl-b inhibitor with IC 50 values range of 5.1-100 nM and ﹤1 nM in high and low concentration of Cbl-b, respectively [1]. Cell Viability Assay [1] Cell Line: Immune cell Concentration: 0.125 nM, 0.15 nM Incubation Time: 1 h Result: Showed Cbl-b activity with an with IC 50 values range of 5.1-100 nM and ﹤1 nM in high and low concentration of Cbl-b, respectively.

2503325-21-9

C29H30F5N5O2

575.57

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years